Mindfulness-Based Cognitive Therapy + Safety Planning For Suicidal Behavior
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01826240|
Recruitment Status : Completed
First Posted : April 8, 2013
Last Update Posted : December 4, 2015
|Condition or disease||Intervention/treatment||Phase|
|Monopolar Depression, Single Episode or Unspecified Suicidal and Self-injurious Behaviour||Behavioral: MBCT+SPI||Phase 1|
- The study is a nine-week clinical trial combining Safety Planning Intervention plus Mindfulness-Based Cognitive Therapy for patients with a recent history of suicidal thoughts or behavior and current or past depressive symptoms.
- These treatments work for depression and some preliminary data suggest they may work to prevent suicidal behavior.
- Nine weeks of free treatment
- Clinical assessments
- An opportunity to offer your views on treatment and suggestions for improving the treatment in focus groups
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Mindfulness-Based Cognitive Therapy + Safety Planning For Suicidal Behavior: A Treatment Development Study|
|Study Start Date :||March 2013|
|Actual Primary Completion Date :||February 2015|
|Actual Study Completion Date :||February 2015|
Note: There is only one condition in this study. Mindfulness-Based Cognitive Therapy (MBCT) is combined with Safety Planning Intervention (SPI). All individuals who choose to participate will receive MBCT+SPI.
Safety Planning Intervention (SPI), a very brief intervention focused on identifying personalized coping strategies to manage acute suicidality, is combined with Mindfulness-Based Cognitive Therapy (MBCT), a group intervention comprised of mindfulness training and cognitive therapy techniques. Treatment lasts 9 weeks.
- Retention [ Time Frame: participants will be followed for the duration of treatment, an expected average of 9 weeks ]Feasibility
- Consumer Satisfaction Questionnaire [ Time Frame: post-treatment (at 9 weeks) ]Acceptability
- Change in scores on Scale for Suicide Ideation [ Time Frame: participants will be followed for the duration of treatment, an expected average of 9 weeks ]Safety
- Change in scores on Beck Depression Inventory (BDI-II) [ Time Frame: baseline and post-treatment (at 9 weeks) ]Effectiveness
- Change in cognitive processes underlying treatment gains [ Time Frame: baseline and post-treatment (at 9 weeks) ]neuropsychological tasks assessing attention and other cognitive processes
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01826240
|United States, New York|
|Columbia University/New York State Psychiatric Institute|
|New York, New York, United States, 10032|
|Principal Investigator:||Megan Chesin, Ph.D.||Columbia University|